Frontlight ResearchEarly access
CompletedPhase 2
Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder
Key facts
- Who runs it
- Universitaetsmedizin Goettingen
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 50 people enrolled
- Started
- 20 Mar 2023
- Ended
- 4 Mar 2026
- Type of study
- Interventional
- Record updated
- 23 July 2024
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patients with BED according to DSM-5
- Male or female patients aged between 18 and 40 (the upper age limit was chosen to minimise potential confounding effects by hormonal changes related to menopause)
- Written informed consent obtained according to international guidelines and local laws
- Ability to understand the nature of the trial and the trial related procedures and to comply with them
Who cannot take part
- current or planned use of psychotropic medication (during the period of the study)
- current diagnosis of a psychotic, bipolar, or substance use disorder
- severe somatic illness (e.g. cancer, cardiovascular disease, instable diabetes mellitus; blood pressure ≥ 160/100 mmHg at rest and/or current treatment of hypertensive crisis within last 6 months)
- known hypersensitivity to hydrocortisone
- known glucose-galactose malabsorption
- systemic (i.v. or oral) glucocorticoid treatment within the last 3 months
- known pheochromocytoma
- Simultaneous participation in another interventional trial
- Pregnant or breastfeeding females
- current or planned psychotherapy (during the period of the study)
- known hereditary galactose intolerance
- known lactase deficiency
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The central research question of this project is whether a combination of (food) exposure with response prevention (ERP) and cortisol is superior to ERP under placebo in terms of the reduction of craving for food in Binge Eating Disorder (BED).
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 23 July 2024